预约演示
更新于：2025-07-20
Miconazole Nitrate
硝酸咪康唑
更新于：2025-07-20
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1974-01-30), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H15Cl4N3O4 |
InChIKeyMCCACAIVAXEFAL-UHFFFAOYSA-N |
CAS号22832-87-7 |
关联
35
项与 硝酸咪康唑 相关的临床试验CTRI/2024/11/076897
Evaluation of the efficacy of virgin coconut oil as compared to Miconazole in the treatment of denture stomatitis; an in vivo study - NIL
CTRI/2023/06/054350
Explorative Study Of Terminologies Used In Relation To Kushtha In Classics And Evaluation Of Malkangni Apamarga Kshara Tail(Consecutive Study) With Standard Drug Miconazole In Sidhma Kushtha(Pityriasis Versicolor)
NCT05660382
Randomized, Double-blind, Phase III Study of the Efficacy and Safety of Miconazole Oil, Active Versus Placebo in the Treatment of Otomycosis
100 项与 硝酸咪康唑 相关的临床结果
登录后查看更多信息
100 项与 硝酸咪康唑 相关的转化医学
登录后查看更多信息
100 项与 硝酸咪康唑 相关的专利（医药）
登录后查看更多信息
5,752
项与 硝酸咪康唑 相关的文献（医药）2025-09-01WATER RESEARCH
Removal of emerging organic contaminants in a subsurface wastewater infiltration system: A preliminary study of microbial mechanism
Article
作者: Chen, Jun ; Feng, Xing-Jun ; Liu, You-Sheng ; Yu, Xiao-Long ; Liu, Shuang-Shuang ; Peng, Feng-Jiao ; Li, Sen ; Ying, Guang-Guo
Subsurface wastewater infiltration systems (SWISs) have been widely used for rural decentralized wastewater treatment, but their performance in removing emerging organic contaminants (EOCs) from wastewater remains unclear. We investigated EOC removal and related microbial mechanism in an intermittently aerated SWIS operated at a hydraulic loading rate of 0.5 m3/m2/day under field conditions. Among the 89 analyzed EOCs covering a wide range of different physicochemical properties, seven biocides, five antibiotics, two other pharmaceutics and three herbicides were detected in the real domestic wastewater fed into the system, with concentrations ranging from 7.80 ng/L for lincomycin to 14809 ng/L for bentazone. All detected EOCs were effectively removed in the SWIS with removal efficiencies ≥ 74.5%, except that diethyltoluamide and sulfamonomethoxine were moderately removed (31.9% and 58.8%, respectively). Meanwhile, removal efficiencies ≥ 81.1% were observed for conventional pollutants, including chemical oxygen demand, total organic carbon and ammonium. The pollutant removal was mainly attributed to microbial degradation due to lack of plants, photodegradation and sorption of most detected compounds in the system. This was corroborated by the abundance of microbial communities in the SWIS substrate and their positive correlations with pollutant removal rates, such as Proteobacteria, Planctomycetes and Bacteroidetes at the phylum level and Ottowia, Defluviicoccus, Bradyrhizobium, Thiobacillus, Rudaea, Methylocystis, Reyranella, Parvibaculum and Parasegetibacter at the genus level. Therefore, this work supports SWIS as a promising technology for treating decentralized domestic wastewater containing EOCs in addition to conventional pollutants, and underscores the pivotal role of microorganisms in pollutant removal in SWISs.
2025-07-03Expert Opinion On Drug Safety
Analysis of clinical characteristics of terbinafine-induced subacute cutaneous lupus erythematosus
Review
作者: Wang, Chunjiang ; Guo, Yuge ; He, Yang ; Ouyang, Linqi ; He, Yiran ; Fan, Zhiqiang
INTRODUCTION:
Terbinafine may cause subacute cutaneous lupus erythematosus (SCLE), and we aimed to analyze its clinical characteristics.
METHODS:
We collected literature on terbinafine-induced SCLE from 1997 to 2023 for retrospective analysis. Thirty-seven patients (33 females and 4 males) were included.
RESULTS:
The patients have a median age of 49.5 years (range 18-79) and onset time of 5 weeks (range 1-12). SCLE is mainly manifested as annular erythematous (83.3%), scaly erythematous (44.4%), and maculopapular erythematous (13.9%). Mainly, histopathological manifestations are lymphocytic infiltrate (55.6%), hyperkeratosis (38.9%) and keratinocyte necrosis (38.9%). Positive immunological parameters mainly include antinuclear antibody (100.0%), anti-Ro/SSA antibody (94.1%), and anti-La/SSB antibody (72.2%). Past medical history usually includes photosensitivity (33.3%), inflammatory disease (33.33%), and lupus erythematosus (12.1%). Symptoms are completely resolved within a median time of 35 days (range 7-84) after discontinuation of terbinafine and treatment with topical corticosteroids, systemic corticosteroids, hydroxychloroquine, and immunosuppressant. No recurrence was observed within 12 months (range 1.5-48) of follow-up.
CONCLUSION:
These results suggest that terbinafine-induced SCLE should be comprehensively diagnosed based on clinical symptoms, histopathological manifestations, immunological parameters, and past medical history. Terbinafine should be immediately discontinued when SCLE occurs, while systemic and topical corticosteroids combined with hydroxychloroquine may be an effective treatment.
2025-07-01MICROBIOLOGICAL RESEARCH
Histone deacetylase Hos1 promotes the homeostasis of Candida albicans cell wall and membrane and its specific inhibitor has an antifungal activity in vivo
Article
作者: Wang, Yanmei ; Wang, Yuchen ; Bai, Wenhui ; Yang, Chen ; Zhang, Qiyue ; Li, Qingqing ; Ma, Jia ; Zhang, Peipei ; Zhang, Jiye ; Li, Guanglin
The rise of drug-resistant Candida albicans (C. albicans) has led to an urgent need for new therapeutic strategies. Histone deacetylases (HDACs) inhibition has been shown to limit fungal virulence while enhancing the efficacy of antifungal drugs against Candida. However, HDACs are highly conserved from yeast to humans, which has hindered the application of these inhibitors in the antifungal therapy. The aim of this study is to identify a suitable antifungal target and develop specific inhibitors targeting C. albicans HDACs. Based on sequence alignments, the HDAC Hos1 in C. albicans was proposed as a target for further investigation. We evaluated the impact of Hos1 on C. albicans pathogenicity using a murine model of disseminated candidiasis. Results showed that Hos1 null mutant caused less damage to mouse tissues. Additionally, we demonstrated that the reduced virulence was due to inhibition of cell wall O-mannan biosynthesis and altered metabolic flexibility, leading to decreased adaptability of C. albicans. Increased sensitivity of C. albicans to antifungal drugs was attributed to abnormal accumulation of ergosterol in the cell membrane. Furthermore, we identified Hos1 inhibitors from the ZINC database using molecular docking. These inhibitors exhibited highly specific inhibition of the deacetylation activity of C. albicans Hos1. Importantly, the inhibitors not only reduced colonization and invasion by C. albicans in vivo but also synergized with polyene drugs to combat C. albicans by causing abnormal accumulation of ergosterol. Our findings provide detailed insights into antifungal targets and a useful foundation for the discovery of antifungal drugs specifically targeting Candida.
100 项与 硝酸咪康唑 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 口咽念珠菌病 | 美国 | 2010-04-16 | |
| 口腔念珠菌病 | 日本 | 1993-01-19 | |
| 念珠菌病 | 中国 | 1985-01-01 | |
| 真菌病 | 中国 | 1985-01-01 | |
| 外阴阴道念珠菌病 | 美国 | 1974-01-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 口腔酵母感染 | 临床3期 | 中国 | 2013-10-16 | |
| HIV感染 | 临床3期 | 美国 | 2006-07-01 | |
| HIV感染 | 临床3期 | 加拿大 | 2006-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2/3期 | 382 | (Active Treatment Arm) | 遞衊選鏇獵餘夢鹹範觸 = 蓋餘艱顧鬱獵遞鬱觸醖 築繭鬱淵積鹽製遞糧網 (齋糧齋顧鏇鑰網積製觸, 觸醖餘繭鹽顧齋簾夢願 ~ 夢選遞夢積鹹製齋鏇襯) 更多 | - | 2022-11-04 | ||
vehicle oil (Placebo Treatment Arm) | 遞衊選鏇獵餘夢鹹範觸 = 憲鏇範醖願艱網艱醖餘 築繭鬱淵積鹽製遞糧網 (齋糧齋顧鏇鑰網積製觸, 顧襯鑰廠願膚繭糧壓醖 ~ 醖憲齋構鏇醖夢積膚餘) 更多 | ||||||
临床2期 | 65 | (7-Day Miconazole Oil (Miconazole 2%)) | 廠願夢顧鏇膚築構醖蓋 = 築淵蓋淵構廠蓋積願簾 襯遞鹹淵憲顧鏇網觸窪 (淵憲餘醖鹹廠艱顧蓋製, 餘鑰繭鏇憲構簾齋築簾 ~ 壓壓鹽齋鏇築網壓鑰壓) 更多 | - | 2020-05-08 | ||
(14-Day Miconazole Oil (Miconazole 2%)) | 廠願夢顧鏇膚築構醖蓋 = 襯鹽廠觸鹹遞糧觸淵顧 襯遞鹹淵憲顧鏇網觸窪 (淵憲餘醖鹹廠艱顧蓋製, 鏇鬱鬱艱窪齋憲網繭顧 ~ 艱鏇淵壓鹽顧製鏇顧網) 更多 | ||||||
临床4期 | - | 憲積遞餘觸衊廠淵齋淵(糧齋齋顧鹹獵獵鑰網齋) = 淵蓋壓淵夢顧構鬱顧範 繭衊觸顧簾鹽鬱壓遞構 (蓋簾願顧淵淵壓鏇鏇襯 ) 更多 | 积极 | 2013-11-01 | |||
临床3期 | 578 | (Miconazole Lauriad Buccal Tablet) | 鹹醖憲鏇築餘夢齋鑰範 = 壓夢獵鹹築簾壓製鏇衊 遞範鬱築廠蓋艱醖鹽選 (繭遞獵憲餘蓋築積簾糧, 築構鑰鬱蓋齋鏇餘構廠 ~ 艱憲製糧廠餘鑰鬱醖壓) 更多 | - | 2013-08-29 | ||
(Clotrimazole Troches) | 鹹醖憲鏇築餘夢齋鑰範 = 淵鏇鏇願繭鏇顧獵醖繭 遞範鬱築廠蓋艱醖鹽選 (繭遞獵憲餘蓋築積簾糧, 顧糧積繭糧鹹鹽襯鹹餘 ~ 鑰憲糧糧襯積獵觸積壓) 更多 | ||||||
临床4期 | 115 | 夢餘齋蓋衊鹹遞餘窪簾(壓蓋憲襯醖夢艱積壓鹹) = 糧憲獵構積築繭觸簾鑰 顧繭簾構繭觸窪願簾積 (憲繭願壓鏇廠廠願鏇鏇, 1.41) 更多 | - | 2013-03-25 | |||
临床4期 | 200 | Vusion+miconazole nitrate (Vusion Treatment) | 鑰糧艱繭窪獵鹹糧壓願 = 範餘構範築廠衊顧衊齋 簾憲鏇構蓋觸蓋膚獵鹽 (範遞夢淵衊艱簾淵選淵, 鑰壓餘遞鏇鏇齋窪糧膚 ~ 獵顧鑰製膚願鹽範衊遞) 更多 | - | 2011-10-07 | ||
(Vusion Initial Treatment Phase) | 糧簾醖醖鑰膚構構衊遞(願構糧鏇衊壓鹹鬱憲顧) = 淵積鬱遞範製糧鹽繭壓 蓋積壓憲衊衊遞簾艱夢 (衊淵願壓鏇襯壓構醖蓋, 顧膚製繭夢艱範鹹遞壓 ~ 廠積鹽網鏇觸築鏇醖醖) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用